World journal of diabetes · 2025
Lactobacillus rhamnosus LRa05 on glycemic control and gut microbiota in patients with type 2 diabetes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Geng Lin, Sun Ting-Ting, Xia Wen-Bo, Qin Yin, Huo Di, Qu Guang-Jing
Аннотация
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a metabolic disorder linked to high blood glucose and gut dysbiosis. Probiotics like Lactobacillus rhamnosus LRa05 may improve glycemic control and gut microbiota.
AIM: To explore the impact of LRa05 with hypoglycemic medications on glycemic control and intestinal flora in T2DM patients with gut dysbiosis.
METHODS: Seventy-six participants were randomly assigned to receive either LRa05 (0.1 g 2 × 1010 CFU) (n = 38) or a placebo (n = 38) for 12 weeks. Baseline characteristics were recorded, and changes in glycated hemoglobin, fasting blood glucose, and other biochemical indices were assessed using repeated measures one-way analysis of variance. Additionally, gut microbiota diversity was analyzed through species accumulation and alpha and beta diversity metrics.
RESULTS: The intervention group showed statistically significant improvements in lipid profiles, particularly in high-density lipoprotein cholesterol levels, which increased significantly over time (P < 0.001). Additionally, fasting blood glucose was significantly reduced in the LRa05 group compared with the placebo group (P < 0.001). No significant changes were observed in glycated hemoglobin, insulin sensitivity, or systemic inflammatory markers such as C-reactive protein. Furthermore, gut microbiota analysis revealed significant shifts in composition following the intervention, particularly an increase in Bifidobacterium and a decrease in Bacillota, indicating beneficial effects on gut health.
CONCLUSION: This study demonstrated that the combination of Lactobacillus rhamnosus LRa05 and hypoglycemic medications positively impacted glycemic control, specifically reflected in improved levels of high-density lipoprotein and fasting blood glucose. Additionally, significant alterations in gut microbiota composition were observed in patients with T2DM, indicating a potential synergistic effect between gut health and blood glucose regulation.
AIM: To explore the impact of LRa05 with hypoglycemic medications on glycemic control and intestinal flora in T2DM patients with gut dysbiosis.
METHODS: Seventy-six participants were randomly assigned to receive either LRa05 (0.1 g 2 × 1010 CFU) (n = 38) or a placebo (n = 38) for 12 weeks. Baseline characteristics were recorded, and changes in glycated hemoglobin, fasting blood glucose, and other biochemical indices were assessed using repeated measures one-way analysis of variance. Additionally, gut microbiota diversity was analyzed through species accumulation and alpha and beta diversity metrics.
RESULTS: The intervention group showed statistically significant improvements in lipid profiles, particularly in high-density lipoprotein cholesterol levels, which increased significantly over time (P < 0.001). Additionally, fasting blood glucose was significantly reduced in the LRa05 group compared with the placebo group (P < 0.001). No significant changes were observed in glycated hemoglobin, insulin sensitivity, or systemic inflammatory markers such as C-reactive protein. Furthermore, gut microbiota analysis revealed significant shifts in composition following the intervention, particularly an increase in Bifidobacterium and a decrease in Bacillota, indicating beneficial effects on gut health.
CONCLUSION: This study demonstrated that the combination of Lactobacillus rhamnosus LRa05 and hypoglycemic medications positively impacted glycemic control, specifically reflected in improved levels of high-density lipoprotein and fasting blood glucose. Additionally, significant alterations in gut microbiota composition were observed in patients with T2DM, indicating a potential synergistic effect between gut health and blood glucose regulation.